Facebook Instagram Twitter Linkedin Youtube Podcast

Duchenne News Tags: Italfarmaco

Search
Tags
Tags
Antisense Therapeutics Astellas Avidity Biosciences Dyne Edgewise Entrada Therapeutics FibroGen Italfarmaco NS Pharma PepGen Pliant Therapeutics PTC Therapeutics REGENXBIO Santhera Sarepta Solid Biosciences Wave Life Sciences
July 5, 2023

Italfarmaco Group Completes FDA Submission of New Drug Application for Givinostat in Duchenne and Receives Priority Review

Italfarmaco announces that the FDA has completed filing review and accepted the company’s NDA for Givinostat.
Read More
June 27, 2022

Italfarmaco Group Announces Positive Topline Data from Phase 3 Trial Showing Beneficial Effect of Givinostat in Patients with Duchenne Muscular Dystrophy

On Saturday, June 25, 2022, Italfarmaco Group shared a press release regarding positive topline data from its completed Phase 3 EPIDYS trial with Givinostat.
Read More

Jett Foundation, Inc.
65 Cordage Park Circle
Suite 130 | Plymouth, MA 02360
781-585-5566 | info@jettfoundation.org

Gold Transparency 2022 Candid. Logo
Sitemap
© 2023 All rights reserved. Powered by Getfused

Support Jett Foundation

Donate Today
Jett Foundation, Inc. is a 501(c)3 registered tax-exempt nonprofit organization. Our Federal Tax ID is 04-3563445.

Stay Connected With Us

Sign up to receive our newsletter and updates.
Required fields are denoted with an asterisk (*)





    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

    Experience the magic of camp promise

    Complete applications due April 3, 2023.
    Apply Now